Dr. Katie Murray discusses emerging strategies for non–muscle invasive bladder cancer, particularly in the BCG-naive and high-risk settings. Ongoing trials are exploring combinations of BCG with immunotherapy, alternatives like gemcitabine and docetaxel, and new FDA-approved agents to expand frontline options. Biomarkers, including computational histology (CHAI), may help predict patient response to specific therapies and guide […]

ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.

Dr. Katie Murray and oncology nurse practitioner Laura Bauer discuss the practical challenges of delivering new FDA-approved therapies for non–muscle invasive bladder cancer and why strong collaboration between urology and medical oncology is essential. They highlight strategies to prevent patients from being lost to follow-up, coordinate cystoscopy surveillance, manage expensive drug preparation, and ensure smooth […]

Dr. Katie Murray and GU oncology nurse practitioner Laura Bauer discuss how multidisciplinary collaboration is becoming increasingly important in managing non–muscle invasive bladder cancer. They highlight how integrating medical oncology teams helps manage intravesical therapies, coordinate treatment logistics, and expand access to newer agents such as gemcitabine/docetaxel, nadofaragene firadenovec, N-803, and mitomycin hydrogel. As treatment […]

Dr. Katie Murray reviews the management of intermediate-risk non–muscle invasive bladder cancer, focusing on patients with recurrent low-grade tumors who often undergo repeated surgeries. She highlights the emerging role of chemoablative therapy, including the FDA-approved intravesical mitomycin hydrogel (Zesduri), which may help reduce repeat TURBT procedures while preserving the bladder.

Dr. Katie Murray highlights the expanding treatment landscape for high-risk non–muscle invasive bladder cancer, especially for patients who are unresponsive to BCG. Options now include BCG re-challenge, doublet intravesical chemotherapy, systemic immunotherapy with pembrolizumab, intravesical gene-based therapies, and recently FDA-approved intravesical devices. Treatment decisions consider efficacy, side effect profiles, and administration schedules, while radical cystectomy […]

High-risk non-muscle-invasive bladder cancer (NMIBC) remains a clinically challenging disease state despite intravesical bacillus Calmette-Guérin (BCG), with substantial rates of recurrence and progression. Enhancing upfront immunologic control in BCG-naïve patients represents a critical opportunity to improve long-term outcomes. The phase III POTOMAC trial evaluated whether adding systemic programmed death-ligand 1 (PD-L1) inhibition with durvalumab to […]

Dr. Katie Murray discusses how advances in non–muscle invasive bladder cancer are shifting care toward a more collaborative, practice-wide model. She emphasizes the growing role of nurses and advanced practice providers in intravesical therapy delivery, patient education, and symptom management. As treatment expands beyond repeated TURBTs, Dr. Murray highlights the need for the entire care […]